Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Fusion Pharmaceuticals Inc

CUSIP: 36118A900 | 5 institutional holders

Quarters

Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023

Compare Detailed Historical Funds Options Short Interest 13D/13G Peers Targeting Trading Summary Profile